| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Richard James Goodall | Q89448796 |
| P2093 | author name string | Andrew Bryant | |
| Jo Morrison | |||
| Kezia Gaitskell | |||
| Clemens Thoma | |||
| Thomas J Lyons | |||
| Alison J Wiggans | |||
| P2860 | cites work | Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer | Q24201686 |
| Epidermal growth factor receptor blockers for the treatment of ovarian cancer | Q24236143 | ||
| Epidermal growth factor receptor blockers for the treatment of ovarian cancer | Q24240840 | ||
| Grading quality of evidence and strength of recommendations | Q24562409 | ||
| EGFR/HER-targeted therapeutics in ovarian cancer | Q26863231 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials | Q29619501 | ||
| Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study | Q33378256 | ||
| A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. | Q33380697 | ||
| Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma | Q33395016 | ||
| A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors | Q33401450 | ||
| Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial | Q33403609 | ||
| Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. | Q33903078 | ||
| Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group | Q33909830 | ||
| Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. | Q34147360 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Mechanism of action of trastuzumab and scientific update | Q34437163 | ||
| Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. | Q34528550 | ||
| Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer | Q34781970 | ||
| The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer | Q36135007 | ||
| Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. | Q36245116 | ||
| A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. | Q36696463 | ||
| Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails | Q37002174 | ||
| The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer | Q37021444 | ||
| New therapies for ovarian cancer: cytotoxics and molecularly targeted agents | Q37110610 | ||
| Targeting EGFR and PI3K pathways in ovarian cancer | Q37214329 | ||
| Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia | Q37235598 | ||
| Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash | Q37340624 | ||
| A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer | Q37423291 | ||
| The role of the fallopian tube in the origin of ovarian cancer | Q37608093 | ||
| A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study | Q37677618 | ||
| GRADE guidelines: 5. Rating the quality of evidence--publication bias | Q37908618 | ||
| Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. | Q38376696 | ||
| Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer | Q38419271 | ||
| Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer | Q38441379 | ||
| Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). | Q38857412 | ||
| Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust | Q40587507 | ||
| Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. | Q40959114 | ||
| Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. | Q41721778 | ||
| A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). | Q42963970 | ||
| Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer | Q43092698 | ||
| Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). | Q43181709 | ||
| Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. | Q43606283 | ||
| Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo | Q43829350 | ||
| Revised FIGO staging for gynaecological cancer | Q44043237 | ||
| ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. | Q44106085 | ||
| Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). | Q44324783 | ||
| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer | Q44461877 | ||
| Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer | Q45357596 | ||
| Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study | Q46630310 | ||
| Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study | Q46712990 | ||
| Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecologi | Q48110100 | ||
| A new index of priority symptoms in advanced ovarian cancer. | Q48762319 | ||
| Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors | Q52297317 | ||
| Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. | Q52678697 | ||
| Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. | Q53554133 | ||
| Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. | Q54076350 | ||
| Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status | Q57217085 | ||
| A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer | Q57975564 | ||
| Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors | Q71805186 | ||
| Expression of cytokines and receptors in normal, immortalized, and malignant ovarian epithelial cell lines | Q73823145 | ||
| Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model | Q77555291 | ||
| Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 | ||
| A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies | Q79382565 | ||
| Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6) | Q79426026 | ||
| Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors | Q84553767 | ||
| A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors | Q84560039 | ||
| A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies | Q84912549 | ||
| Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study | Q85610767 | ||
| A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer | Q87356244 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | CD007927 | |
| P577 | publication date | 2018-10-16 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Epidermal growth factor receptor blockers for the treatment of ovarian cancer | |
| P478 | volume | 10 |
| Q89977247 | Factors in Oncogenesis: Viral Infections in Ovarian Cancer |
| Q59800580 | Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma |
| Q92856177 | The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance |
| Q64062159 | Therapeutic Targeting of Collective Invasion in Ovarian Cancer |
Search more.